- Tonix Pharmaceuticals Holding (NASDAQ:TNXP) jumps 8% premarket after signing a Purchase and Sale Agreement to acquire an ~48,000 square foot R&D facility in Frederick, MD to support its expanding infectious disease pipeline.
- Tonix agreed to purchase the R&D facility from Southern Research. The facility currently operates at biosafety level 2 (BSL-2) containment.
- Tonix expects the transaction to close and the facility to be operational in Q4 2021.
- Tonix and Southern Research plan to continue those aspects of their collaboration on the development of vaccines and antivirals that are ongoing at the Birmingham, AL campus.